Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190970 · ClinicalTrials.gov registry record · Phase 2
The Effect of Ruboxistaurin on Small Fiber Function
A Phase 2 study of Diabetic Neuropathy, sponsored by Chromaderm.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00190970 is a Phase 2 study of Diabetic Neuropathy that has completed, run by Chromaderm. The registered enrollment target is 52 participants, below the 178-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00190970, a Phase 2 study of Diabetic Neuropathy, has completed, sponsored by Chromaderm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effect of Ruboxistaurin on small fiber function.
Conditions Studied
Interventions
- DRUG Ruboxistaurin
Study Locations (1)
Virginia
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190970
The ClinicalTrials.gov registry entry for NCT00190970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (71% lower). The listed sponsor is Chromaderm, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Ruboxistaurin is the first listed.
NCT00190970 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT00190970 about?
NCT00190970 is a clinical study titled "The Effect of Ruboxistaurin on Small Fiber Function". To determine the effect of Ruboxistaurin on small fiber function.
What is the current status of trial NCT00190970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2004-10. Estimated completion is 2005-11.
What conditions does trial NCT00190970 study?
This clinical trial studies the following conditions: Diabetic Neuropathy.
What interventions are being tested in trial NCT00190970?
The interventions under investigation include: Ruboxistaurin (DRUG).
Who is sponsoring clinical trial NCT00190970?
This trial is sponsored by Chromaderm, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00190970 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy
COMPLETED · Phase 2
-
Study of DA-9801 to Treat Diabetic Neuropathy
COMPLETED · Phase 2
-
The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy
COMPLETED · Phase 2
-
Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks
RECRUITING · NA
-
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
ACTIVE NOT RECRUITING
-
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.